The First Affiliated Hospital of Guangxi Medical University
Nanning, Guangxi, 530021, China
NCT Number: NCT06680115
To evaluate the efficacy and safety of neoadjuvant and adjuvant Sintilimab combined with chemoradiotherapy versus chemoradiotherapy alone in stage TanyN3M0 nasopharyngeal carcinoma. The primary endpoint was 2-year failure-free survival (FFS). Secondary endpoints included 2-year overall survival (OS), distant failure-free survival (DFFS), locoregional failure-free survival (LRFFS), and adverse events.
Trial opening soon.
Get Notified18 year and older
All sexes
Interventional
Phase 2
Nanning, Guangxi, 530021, China
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Induction chemotherapy stage: Sintilimab combined with GP regimen chemotherapy; Adjuvant chemotherapy stage: Sintilimab combined with Capecitabine
Time frame: 2 years
Time frame: 2 years
Time frame: 2 years
Time frame: 2 years
Contact information is provided by the study sponsor or research team.
First Affiliated Hospital of Guangxi Medical University
Other
Neoadjuvant and Adjuvant Sintilimab Combined with Chemoradiotherapy Versus Chemoradiotherapy Alone in Stage TanyN3M0 Nasopharyngeal Carcinoma: a Multicenter, Open-label, Randomized Phase II Clinical Trial
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07064902
Carcinoma, Head and Neck Neoplasms
Xiamen, Fujian, China
View Trial DetailsNCT07674706
Carcinoma, Carcinoma, Squamous Cell
Singapore
View Trial DetailsNCT07303283
Adjuvant Therapy, Carcinoma
Nanning, Guangxi, China
View Trial DetailsNCT07567742
Carcinoma, Head and Neck Neoplasms
Guangzhou, Guangdong, China
View Trial Details